Hepatocellular carcinoma (HCC) mortality rates are increasing globally, and particularly in
the Western world. Cirrhosis remains the predominant risk factor for HCC. However …

Hepatocellular carcinoma (HCC) is one of the leading cancers worldwide. Classically, HCC
develops in genetically susceptible individuals who are exposed to risk factors, especially in …

Metabolic dysfunction-associated steatotic liver disease (MASLD) is the latest term for
steatotic liver disease associated with metabolic syndrome. MASLD is the most common …

Background No adjuvant treatment has been established for patients who remain at high
risk for hepatocellular carcinoma recurrence after curative-intent resection or ablation. We …

Nonalcoholic fatty liver disease (NAFLD), including its more severe manifestation,
nonalcoholic steatohepatitis (NASH), has a global prevalence of 20–25% and is a major …

Background ChatGPT-4 is the latest release of a novel artificial intelligence (AI) chatbot able
to answer freely formulated and complex questions. In the near future, ChatGPT could …

Background Cabozantinib has shown clinical activity in combination with checkpoint
inhibitors in solid tumours. The COSMIC-312 trial assessed cabozantinib plus atezolizumab …

Liver cancer, specifically hepatocellular carcinoma (HCC), is the sixth most common cancer
and the third leading cause of cancer mortality worldwide. The development of effective …

Background: Primary liver cancer, of which around 75–85% is hepatocellular carcinoma in
China, is the fourth most common malignancy and the second leading cause of tumor …

PURPOSE Lenvatinib (LEN) is a first-line therapy for patients with advanced hepatocellular
carcinoma (HCC); however, it has shown modest survival benefits. Therefore, we aimed to …